PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 165 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $71,000 | -4.1% | 8,000 | 0.0% | 0.00% | – |
| Q1 2021 | $74,000 | -7.5% | 8,000 | 0.0% | 0.00% | – |
| Q4 2020 | $80,000 | +2.6% | 8,000 | 0.0% | 0.00% | – |
| Q3 2020 | $78,000 | +77.3% | 8,000 | +55.1% | 0.00% | – |
| Q4 2019 | $44,000 | -71.1% | 5,158 | -62.2% | 0.00% | -100.0% |
| Q3 2019 | $152,000 | -46.1% | 13,658 | -38.4% | 0.00% | 0.0% |
| Q2 2019 | $282,000 | -38.8% | 22,158 | +111.0% | 0.00% | -66.7% |
| Q1 2019 | $461,000 | +153.3% | 10,500 | +23.5% | 0.00% | +200.0% |
| Q4 2018 | $182,000 | -60.5% | 8,500 | -19.0% | 0.00% | -66.7% |
| Q3 2018 | $461,000 | -24.3% | 10,500 | -2.8% | 0.00% | -25.0% |
| Q2 2018 | $609,000 | -21.8% | 10,800 | -8.5% | 0.00% | -20.0% |
| Q1 2018 | $779,000 | +281.9% | 11,800 | +337.0% | 0.01% | +150.0% |
| Q3 2015 | $204,000 | -32.7% | 2,700 | +3.8% | 0.00% | -50.0% |
| Q2 2015 | $303,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |